Patents by Inventor Andreas Goutopoulos

Andreas Goutopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N,N-DIMETHYL-4-(7-(N-(1-METHYLCYCLOPROPYL)SULFAMOYL)-IMIDAZO[1,5-A]PYRIDIN-5-YL)PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20250002491
    Abstract: The present invention relates to a compound of formula (I) as PARC inhibitors for the treatment of proliferative disorders, such as e.g. cancer. Preferred compounds are e.g. N,N-dimethyl-4-(7-(N-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl) piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives, such as e.g. the present example 1, N,N-dimethyl-4-(7-(N-(1-methyl-cyclopropyl)sulfamoyl)-1-(6-methylpyridin-3-yl)imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide (II). Experimental data of PARC inhibition assays of exemplary compounds is provided.
    Type: Application
    Filed: October 3, 2022
    Publication date: January 2, 2025
    Applicant: FORX THERAPEUTICS AG
    Inventors: Ulrich Luecking, Andreas Goutopoulos, Jin Tian, Sotirios Sotiriou, Luca Iacovino, Alena Freudenmann, Olivier Querolle
  • PARG INHIBITORY COMPOUNDS
    Publication number: 20240425498
    Abstract: The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.
    Type: Application
    Filed: October 3, 2022
    Publication date: December 26, 2024
    Applicant: FORX THERAPEUTICS AG
    Inventors: Ulrich Luecking, Andreas Goutopoulos, Jin Tian, Sotirios Sotiriou, Luca Iacovino, Alena Freudenmann, Olivier Querolle
  • ACSS2 inhibitors and methods of use thereof
    Patent number: 12133852
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: November 5, 2024
    Assignee: EpiVario, Inc.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • ACSS2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220305010
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Application
    Filed: November 4, 2020
    Publication date: September 29, 2022
    Applicant: METABOMED LTD.
    Inventors: Philippe NAKACHE, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 11098041
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • ACSS2 inhibitors and methods of use thereof
    Patent number: 10851064
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: December 1, 2020
    Assignee: METABOMED LTD.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Patent number: 10517872
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 31, 2019
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20190233417
    Abstract: Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10253023
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: April 9, 2019
    Assignee: Merck Patent GmbH
    Inventors: Pascale Gaillard, Jeyaprakashnarayanan Seenisamy, Lesley Liu-Bujalski, Richard D. Caldwell, Justin Potnick, Hui Qiu, Constantin Neagu, Reinaldo Jones, Annie Cho Won, Andreas Goutopoulos, Brian A. Sherer, Theresa L. Johnson, Anna Gardberg
  • Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
    Patent number: 10233160
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: March 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste DeSelm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors
    Patent number: 9981925
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste Deselm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Benzamides
    Patent number: 9938262
    Abstract: Novel benzamide derivatives of formula (I) wherein W1, W2, R1 to R7, R6, X and Y have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: April 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Andreas Goutopoulos, Thomas E. Richardson, Jiezhen Li, Brian H. Heasley, Pandi Bharathi
  • Indolizine derivatives and their use in neurodegenerative diseases
    Patent number: 9931324
    Abstract: The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: April 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Andreas Goutopoulos
  • Heterocycles as modulators of kinase activity
    Patent number: 9867826
    Abstract: The invention provides novel heterocyclic amines according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: January 16, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Xiaoling Chen, Yufang Xiao, Bayard R. Huck, Andreas Goutopoulos
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9815836
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • Dihydropyrazoles
    Patent number: 9775830
    Abstract: Novel dihydropyrazole derivatives of formula (I) wherein L, R, R3, R4, R5, R6, R7, X1, X2, X3, X4, Y, m and n have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 3, 2017
    Assignee: Merck Patent GmbH
    Inventors: Henry Yu, Thomas E. Richardson, Robert James Foglesong, Lizbeth Celeste Deselm, Andreas Goutopoulos
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9708324
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • Pyridazinone macrocycles as IRAK inhibitors and uses thereof
    Patent number: 9624246
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 18, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Ruoxi Lan, Catherine Jorand-Lebrun, Henry Yu, Andreas Goutopoulos